Skip to content

Topical Oxygen Therapy for BRONJ

Efficacy of Topically Applied Oxygen-Based Therapy Versus Platelet-Rich Fibrin for Medication-Related Osteonecrosis of the Jaws: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07725107
Acronym
OXY-BRONJ Tria
Enrollment
36
Registered
2026-07-24
Start date
2026-04-01
Completion date
2026-09-01
Last updated
2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ), Oxygen, Topical Administration, Wound Healing

Keywords

BRONJ, MRONJ, blue®m, Oxygen-based therapy, Osteonecrosis of the jaw, Wound healing, Oral mucosal healing, Randomized clinical trial

Brief summary

A randomized clinical trial comparing Blue®m oral gel and autologous PRF membrane as adjuncts to surgical debridement in BRONJ/MRONJ patients.

Detailed description

Thirty-six BRONJ/MRONJ patients will be randomly allocated to receive either Blue®m oral gel or PRF membrane following surgical debridement, and healing outcomes will be evaluated clinically.

Interventions

PROCEDURETopical Blue®m application

Intraoperative application of Blue®m oral gel to the debrided surgical site before primary closure

PROCEDUREPRF membrane placement

Intraoperative placement of an autologous PRF membrane over the debrided surgical site before flap closure.

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patient Age: ≥18 years. * Patients diagnosed with BRONJ/MRONJ Stage 1-3 (AAOMS criteria).(25) * History of antiresorptive or antiangiogenic drug use. * Patients willing to participate in the study's follow-up intervals and to provide informed consent.

Exclusion criteria

* Previous radiotherapy to head and neck * Uncontrolled systemic disease (e.g., uncontrolled diabetes) * Pregnancy or lactation * Known allergy to Blue®m components * Uncooperative patients.

Design outcomes

Primary

MeasureTime frameDescription
Complete mucosal healing (bone coverage)12 weeks post-interventionMucosal healing will be evaluated clinically by direct inspection of the surgical site.

Secondary

MeasureTime frameDescription
Soft-Tissue Healing- One week after intervention - 2 weeks after intervention - 4 weeks after intervention - 12 weeks after interventionSoft tissue healing will be assessed using the Landry Healing Index, measured on a 5-point scale.
Postoperative pain- 1 week postoperatively - 4 weeks postoperativelyPain assessment will be evaluated using the Numeric Rating Scale (NRS), measured on a 0-10 scale.
Hard Tissue- Preoperatively - 12 weeks postoperativeBone density will be measured using CBCT at buccal, palatal, and apical aspects at coronal, middle, and apical levels, and the average value will be recorded.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 25, 2026